SUBSCRIBE |
Teva Pharmaceuticals TEVA is anticipating a trough for 2019, but apropos of the company’s name, this is a natural development in the company’s restructuring according to CEO Kare Schultz.
The restructuring plan that will progress over 2019 is also focused on driving down the company’s debt that will tamp down earnings results in the near term but better position the company for future growth in the long term.
To hear more as the plan progresses and an opening of hope possibly appears for the Peta Tikvah-based company appears, stick with TheStreet.
MORE VIDEOS:
ACTION ALERTS PLUS |
RETIREMENT DAILY |
REAL MONEY PRO |
FACEBOOK |
TWITTER |
PODCASTS |
THESTREET.COM |
LINKEDIN |
INSTAGRAM |
Sign up for ActionAlertsPlus.com today for exclusive insight into Jim Cramer’s charitable portfolio:
source
